Novo Nordisk Pharmaceuticals v. Bio-Technology General [Correction]
This text of Novo Nordisk Pharmaceuticals v. Bio-Technology General [Correction] (Novo Nordisk Pharmaceuticals v. Bio-Technology General [Correction]) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
United States Court of Appeals for the Federal Circuit
CORRECTED: October 5, 2005 at 1:00 PM
04-1581
NOVO NORDISK PHARMACEUTICALS, INC., and NOVO NORDISK A/S,
Plaintiffs-Appellants,
v.
BIO-TECHNOLOGY GENERAL CORP. and TEVA PHARMACEUTICALS USA, INC.,
Defendants-Appellees.
Steven E. Lipman, Darby & Darby, P.C., of New York, New York, argued for plaintiffs-appellants. Of counsel were James Edward Hanft, Paul M. Zagar, Jay P. Lessler, Kevin L. Reiner, Robert Schaffer and Joseph R. Robinson.
John W. Bateman, Kenyon & Kenyon, of Washington, DC, argued for defendants-appellees. On the brief was Richard L. DeLucia, of New York, New York. Of counsel were Steven J. Lee, and Thomas J. Meloro, of New York, New York, and Kenneth R. Corsello, of Washington, DC.
Appealed from: United States District Court for the District of Delaware . Chief Judge Sue L. Robinson
Free access — add to your briefcase to read the full text and ask questions with AI
Cite This Page — Counsel Stack
Novo Nordisk Pharmaceuticals v. Bio-Technology General [Correction], Counsel Stack Legal Research, https://law.counselstack.com/opinion/novo-nordisk-pharmaceuticals-v-bio-technology-gene-cafc-2005.